PROM1 and neoplasm: GLT8D1 promotes glioma progression by stabilizing CD133 via hypoxia-induced N-linked glycosylation, thereby supporting glioma stem cell maintenance and activating Wnt/β-catenin–dependent tumor growth; its elevated expression is closely associated with higher tumor grade and poor prognosis, underscoring its potential as a therapeutic target (44, 48).